Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper-64 chloride is a radiopharmaceutical precursor used primarily for the radiolabelling of other molecules, enabling their use in positron emission tomography (PET) imaging. It contains the radioactive isotope copper‑64, which emits beta radiation and has a half-life of 12.7 hours. When used as a precursor, it is not administered directly to patients but is instead attached to carrier molecules that target specific tissues or cells in the body. The compound is distributed mainly to the liver and kidneys after administration, with rapid clearance from blood into these organs before redistribution throughout the body. Its primary clinical application is as a diagnostic agent for PET imaging in oncology and other fields where targeted molecular imaging is required[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copper-64 chloride.